Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Superbiotics is a South Korean biotechnology company specializing in the development of microbiome-derived therapeutics, often referred to as "pharmabiotics." As a subsidiary of Bifido Co., Ltd., the company leverages a proprietary platform to identify and characterize human-origin Bifidobacterium and Lactobacillus strains with clinical potential. Their lead program, BGN4, is currently being evaluated in clinical trials for atopic dermatitis and is in pre-clinical development for rheumatoid arthritis. The company also conducts research into the gut-brain axis for neurodegenerative conditions like Alzheimer's disease and develops treatments for viral infections such as rotavirus. Superbiotics maintains integrated capabilities ranging from strain discovery to GMP-compliant microbial manufacturing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Superbiotics.